Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05496829 | IMPACT Trial: Intervention to iMProve AdherenCe Equitably | recruiting | N/A | 350 | Columbia UniversityOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT06404983 |
| Opioid-free Anaesthesia in Breast Cancer Surgery |
| recruiting |
| N/A |
| 200 |
| University of IoanninaOTHER |
| 1 |
| May 6, 2026 |
| clinicaltrials |
| NCT06480513 | Cancer Of the BReast Asanas Study (COBRA)(COBRA) | recruiting | N/A | 140 | UMC UtrechtOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06727773 | Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer | recruiting | Phase 2 | 90 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06845319 | NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients(NeoCARD) | recruiting | Phase 2 | 43 | Medical University of South CarolinaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07220135 | Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer(NeoTHERa) | recruiting | Phase 2 | 100 | University of Kansas Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07319195 | Window Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC)(WINIT-BC) | recruiting | Early Phase 1 | 32 | Jennifer ZhangOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07555210 | Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy | recruiting | N/A | 25 | Jessica Mezzanotte SharpeOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05190978 | Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction | recruiting | N/A | 120 | University of California, Los AngelesOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05289258 | Unified Barlow Protocol (UP) in Cancer Survivors for Cognitive Impairments | recruiting | N/A | 123 | Universidad de CórdobaOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05716516 | STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)(ESTHER) | recruiting | Phase 2 | 36 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06905301 | Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice(IMPULSE) | recruiting | — | 240 | Novartis PharmaceuticalsINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT07354919 | Axelopran for Advanced Cancer in Patients Receiving Opioids(AxeCan) | recruiting | Phase 2 | 34 | HealthPartners InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT02732860 | Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host(REFLECT) | recruiting | — | 120 | University Health Network, TorontoOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04169542 | Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery | recruiting | — | 600 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04305834 | Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. | recruiting | Phase 2 | 43 | City of Hope Medical CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04434040 | Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | recruiting | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT06193369 | Digital Peer Navigation for Adolescents and Young Adults With Cancer | recruiting | N/A | 138 | University Health Network, TorontoOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07563621 | Determining the Extent of the Genitourinary Syndrome of Menopause Burden in Breast Cancer Survivors(V-light cohort) | recruiting | — | 264 | Jessa HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05056857 | Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen | recruiting | — | 290 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06817954 | To Evaluate the Effectiveness and Safety of Mastectomy Combined With Immediate Breast Reconstruction in Breast Cancer (NJMU-Reconstruction Cohort) | recruiting | N/A | 800 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07332975 | ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC | recruiting | — | 77 | University of PittsburghOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07387445 | Feasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer. | recruiting | N/A | 40 | University of Illinois at ChicagoOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05608252 | VS-6766+Abema+Fulv in Met HR+/HER- BC | recruiting | Phase 1 / Phase 2 | 63 | Adrienne G. WaksOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07070765 | Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity(SPRINT) | recruiting | N/A | 70 | University of AberdeenOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07547774 | Preoperative Sleep Quality and Postoperative Outcomes in Breast Surgery | recruiting | — | 150 | Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research HospitalOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07558447 | Extracellular Vesicles and Chemotherapy-Induced Peripheral Neuropathy(CHEMOVES) | recruiting | N/A | 120 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04468061 | Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | recruiting | Phase 2 | 110 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06268405 | Positron Emission Mammography and Liquid Biopsy in Women With High-risk Breast Screenings | recruiting | N/A | 100 | University Health Network, TorontoOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06416293 | Widening Aims and Giving Patients a Voice for Expanded Structures in Breast Cancer Care Jointly Developed by Patients and Physicians(WAVES) | recruiting | — | 2,000 | University Hospital AugsburgOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06857669 | Clinical Explorative Optical Breast Investigations(CLEO-B) | recruiting | N/A | 90 | Region SkaneOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07095023 | Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer(OPTIMAL-BC) | recruiting | N/A | 112 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07400523 | Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy | recruiting | Phase 3 | 446 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07553572 | Remote Monitoring and Symptom Management Digital Application(ASSIST) | recruiting | N/A | 60 | Patrick C. Johnson, MDOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT04562623 | Prospective Study of Immune Alterations in Operable Breast and Ovarian Carcinoma(GYNECO-IMM&CO) | recruiting | — | 160 | Centre Leon BerardOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05468034 | Exercise in Metastatic Breast Cancer: EMBody | recruiting | N/A | 100 | Indiana UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07276880 | Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer(P-RAD(+)TN-DCT) | recruiting | Phase 2 | 32 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07552467 | Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors | recruiting | — | 26 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05982093 | Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer(SOLTI-2104) | recruiting | Phase 2 | 96 | SOLTI Breast Cancer Research GroupOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06434064 | Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer | recruiting | Phase 2 | 30 | Roswell Park Cancer InstituteOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06807502 | Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device(PROBE-CTC) | recruiting | N/A | 93 | ScreenCellINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07443943 | A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial(AIMSS-RPS) | recruiting | Phase 2 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04852887 | De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)(DEBRA) | recruiting | Phase 3 | 1,670 | NRG OncologyOTHER | 4 | Apr 23, 2026 | clinicaltrials |
| NCT06889688 | Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer | recruiting | Phase 3 | 246 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06928818 | Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea | recruiting | — | 100 | Seoul National University HospitalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07040891 | A Pilot Trial of "Just ASK™" to Increase Discussions About Breast Cancer Clinical Trials | recruiting | N/A | 80 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07111728 | Intraoperative Margin Assessment in Breast Cancer With HSI-Raman(Spectra-BREAST) | recruiting | — | 104 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07548762 | Endoscopic Skin-Sparing vs. Conventional Mastectomy for Wound Complications in BC | recruiting | N/A | 258 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
Data updated 24 days agoSource updated May 6, 2026source: clinicaltrials